A method of treating a disease that is treatable through inhibition of at least one kinase selected from the group consisting of CDK7, CDK4, CDK6, PIM2, TSSK3, MST4, NEK6, MAP3K, MST3, DDR1, SPHK1, CaMK1, AurA, BRK, CaMK4, and PIM1, the method comprising administering an effective dose of a compound represented by the following formula (1) or a salt thereof to a patient: ##STR00001##

Nutritionally acceptable non-lipid compositions and methods are presented that modulate lipid metabolism, and especially increase LPC concentrations. Consequently, the compositions and methods presented herein will facilitate DHA transport to neural and retinal tissues as well as LA availability for cardiolipin synthesis.

Nutritionally acceptable non-lipid compositions and methods are presented that modulate lipid metabolism, and especially increase LPC concentrations. Consequently, the compositions and methods presented herein will facilitate DHA transport to neural and retinal tissues as well as LA availability for cardiolipin synthesis.

Nutritionally acceptable non-lipid compositions and methods are presented that modulate lipid metabolism, and especially increase LPC concentrations. Consequently, the compositions and methods presented herein will facilitate DHA transport to neural and retinal tissues as well as LA availability for cardiolipin synthesis.

The invention relates to psychoactive medicines including 2C-B, methylone, MBDB, their respective metabolites, isomers, enantiomers, polymorphs, and analogues (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.

The invention relates to psychoactive medicines including 2C-B, methylone, MBDB, their respective metabolites, isomers, enantiomers, polymorphs, and analogues (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.

In an embodiment, the present disclosure pertains to a lice-treating gel composition. In some embodiments, the composition includes piperonyl butoxide with a concentration from about 0.5 to 5 wt/wt %, pyrethrum with a concentration from about 0.1 to 1 wt/wt %, citronella with a concentration from about 0.1 to 1 wt/wt %, lemongrass oil with a concentration from about 0.01 to 0.5 wt/wt %, and tea tree oil with a concentration from about 0.01 to 0.5 wt/wt %. In an additional embodiment, the present disclosure pertains to a lice-treating gel composition including piperonyl butoxide with a concentration of about 3.889 wt/wt %, pyrethrins with a concentration of about 0.6 wt/wt %, citronella with a concentration of about 0.66 wt/wt %, lemongrass oil with a concentration of about 0.14 wt/wt %, and tea tree oil with a concentration of about 0.1 wt/wt %.

In an embodiment, the present disclosure pertains to a lice-treating gel composition. In some embodiments, the composition includes piperonyl butoxide with a concentration from about 0.5 to 5 wt/wt %, pyrethrum with a concentration from about 0.1 to 1 wt/wt %, citronella with a concentration from about 0.1 to 1 wt/wt %, lemongrass oil with a concentration from about 0.01 to 0.5 wt/wt %, and tea tree oil with a concentration from about 0.01 to 0.5 wt/wt %. In an additional embodiment, the present disclosure pertains to a lice-treating gel composition including piperonyl butoxide with a concentration of about 3.889 wt/wt %, pyrethrins with a concentration of about 0.6 wt/wt %, citronella with a concentration of about 0.66 wt/wt %, lemongrass oil with a concentration of about 0.14 wt/wt %, and tea tree oil with a concentration of about 0.1 wt/wt %.

A method of treating movement disorders, by administering an effective amount of a psychedelic to an individual having a movement disorder, and treating the movement disorder.

A composition for use in psychotherapeutic or medical treatment of an R(−) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(−) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(−) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA.